Learning Objectives:

1.   Understand scope and potential impact of cardiorenal and metabolic risk mitigation in type 2 diabetes.

2.   Review evidence on the role of GLP-1 receptor agonists and SGLT2 inhibitors in improving cardiovascular and renal outcomes.

3.   Review updates in guidelines pertaining to use of diabetes therapeutic agents for cardiorenal risk reduction.

Session date: 
04/04/2022 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Vanita R. Aroda, M.D.